Haemonetics Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on July 24, 2026, regarding Haemonetics Corporation (HAE). The filing primarily addresses the results of the 2026 Annual Meeting of Shareholders and the election of a new director.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting outcomes rather than financial performance data.
Material Changes and Corporate Actions
- Director Election: The Board elected Martin Madaus as a director, effective immediately. Dr. Madaus, a Senior Operating Executive at The Carlyle Group, is expected to join the Audit and Governance and Compliance Committees. His annual equity award is valued at approximately $200,000.
- Shareholder Meeting Results: The 2026 Annual Meeting was held on July 24, 2026, with 92.53% of outstanding shares represented (42,051,106 of 45,445,983 shares).
- Director Slate: Shareholders elected eight directors for one-year terms expiring in 2027. All nominees received significant "For" votes, ranging from 38.8 million to 39.7 million.
- Executive Compensation: The advisory vote on executive compensation passed with 39,212,253 "For" votes versus 572,620 "Against" votes.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending April 3, 2027.
- Compensation Plan Amendments:
- 2019 Long-Term Incentive Plan: Approved an amendment authorizing 4,680,000 additional shares for issuance and extending the plan term through 2036.
- 2007 Employee Stock Purchase Plan (ESPP): Approved an amendment extending the plan term through 2036.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, market outlook, or specific risk factors. The document is a procedural report of shareholder actions and board appointments.
Key Facts for Investor Verification
- Verify the impact of the 4,680,000 additional shares authorized under the amended Long-Term Incentive Plan on potential future dilution.
- Confirm the specific committee assignments and voting record of the newly elected director, Martin Madaus, in future filings.
- Review the definitive proxy statement filed on June 9, 2026, for detailed terms of the amended compensation plans referenced in this filing.
- Note the high level of shareholder engagement, with over 92% of shares represented at the annual meeting.